AIM ImmunoTech Inc. (AIM) Earnings History
Net Loss31 years of earnings data (1995–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
AIM ImmunoTech Inc. (AIM) Earnings Overview
As of June 28, 2026, AIM ImmunoTech Inc. (AIM) reported trailing twelve-month net income of -$13M, reflecting +23.2% year-over-year growth. The company earned $-3.05 per diluted share over the past four quarters, with a net profit margin of -15861.4%.
Looking at the long-term picture, AIM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 1995.
AIM ImmunoTech Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMMP (-$128M net income, -1218.0% margin), NKTR (-$158M net income, -297.1% margin), IOVA (-$354M net income, -148.4% margin), AIM has room to improve margins relative to the peer group. Compare AIM vs IMMP →
AIM Earnings vs Peers
Earnings metrics vs comparable public companies
AIM Historical Earnings Data (1995–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$14M | +19.4% | -$11M | $-8.62 | -15861.4% | -11961.4% |
| 2024 | -$17M | +40.2% | -$20M | $-11.22 | -10188.2% | -11630.6% |
| 2023 | -$29M | -48.9% | -$32M | $-21.64 | -14337.6% | -15800.0% |
| 2022 | -$19M | -1.7% | -$20M | $-14.69 | -13790.8% | -14129.7% |
| 2021 | -$19M | -32.8% | -$19M | $-14.67 | -14168.1% | -13954.1% |
| 2020 | -$14M | -53.1% | -$15M | $-16.41 | -8834.4% | -9295.7% |
| 2019 | -$9M | +4.2% | -$12M | $-93.71 | -6717.1% | -8887.9% |
| 2018 | -$10M | -18.8% | -$11M | $-355.19 | -2673.8% | -3132.4% |
| 2017 | -$8M | -10.1% | -$11M | $-463.19 | -1889.9% | -2612.4% |
| 2016 | -$8M | +50.7% | -$14M | $-543.05 | -8154.3% | -15004.3% |
| 2015 | -$15M | +12.7% | -$17M | $-1149.98 | -11451.1% | -12518.8% |
| 2014 | -$17M | -7.6% | -$19M | $-1724.98 | -8857.9% | -9694.9% |
| 2013 | -$16M | +6.5% | -$17M | $-1916.64 | -10816.7% | -11444.7% |
| 2012 | -$17M | -92.5% | -$20M | $-2299.97 | -8147.4% | -9549.3% |
| 2011 | -$9M | +31.4% | -$14M | $-1341.65 | -5599.4% | -8878.9% |
| 2010 | -$13M | +2.2% | -$16M | $-1916.64 | -9730.4% | -12138.5% |
| 2009 | -$13M | -10.0% | -$13M | $-1341.65 | -12106.3% | -11949.5% |
| 2008 | -$12M | +32.6% | -$13M | $-3066.62 | -4610.9% | -4834.3% |
| 2007 | -$18M | +6.5% | -$19M | $-4791.60 | -1712.8% | -1771.8% |
| 2006 | -$19M | -55.9% | -$19M | $-5941.58 | -2079.2% | -2003.6% |
| 2005 | -$12M | +46.8% | -$10M | $-4599.94 | -1149.2% | -915.5% |
| 2004 | -$23M | -67.2% | -$11M | $-102.41 | -1903.8% | -886.0% |
| 2003 | -$14M | -88.5% | -$7M | $-82.42 | -2129.8% | -1103.8% |
| 2002 | -$7M | +18.3% | -$7M | $-44.35 | -2177.1% | -1941.3% |
| 2001 | -$9M | -6.2% | -$9M | $-55.39 | -2329.0% | -2256.9% |
| 2000 | -$9M | +30.5% | -$9M | $-56.04 | -1085.3% | -1147.6% |
| 1999 | -$12M | -68.5% | -$13M | $-90.08 | -1756.9% | -1825.7% |
| 1998 | -$7M | -19.7% | -$7M | $-61.33 | -1825.0% | -1800.0% |
| 1997 | -$6M | -32.6% | -$6M | $-67.08 | -2033.3% | -2133.3% |
| 1996 | -$5M | -155.6% | -$5M | $-56.09 | -4600.0% | -4800.0% |
| 1995 | -$2M | - | -$1M | $-34.50 | -60.0% | -33.3% |
Download Data
Export AIM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AIM — Frequently Asked Questions
Quick answers to the most common questions about buying AIM stock.
What is AIM earnings per share (EPS)?
AIM trailing twelve-month (TTM) diluted EPS is $-3.05, reflecting +23.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1995 to 2025 is available in the table on this page.
What is AIM ImmunoTech Inc.'s net income?
AIM ImmunoTech Inc. (AIM) trailing twelve-month net income is $-13M as of 2025. Earnings grew +23.2% year-over-year.
Is AIM profitable?
AIM is not currently profitable on a TTM basis, reporting a net loss of $-13M. Net margin is -15861.4%. Investors should monitor for a return to profitability.
What is AIM's earnings growth rate?
AIM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1995 to 2025.
What are AIM's profit margins?
AIM ImmunoTech Inc. net profit margin is -15861.4%, operating margin is -11961.4%, and gross margin is -284.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is AIM growing earnings?
Yes, AIM earnings are accelerating — EPS growth of +23.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-13M. Earnings momentum is strengthening.
What was AIM's best earnings year?
AIM ImmunoTech Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 1995. Earnings history on this page spans 1995 to 2025 and includes all annual and quarterly figures.
What were AIM's earnings last quarter?
AIM's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.69. For a full breakdown of all quarters, see the quarterly earnings table on this page.